Voices from the Doximity Network
Aleksandra Polic, MD
Feb 26, 2019
Tani Malhotra, MD
Feb 25, 2019 Link to A Presentation at SMFM Reminded Me to Check My Implicit Biases
Brian Iriye, MD
Feb 20, 2019 Link to SMFM Conference Is 'About the Science' and the Local Community
Doximity
Feb 15, 2019 Link to ASCO GU 2019: Evolving Management of Metastatic Renal Cell Carcinoma
Alexander Iribarne, MD MS
Feb 4, 2019 Link to STS Presentations Highlight Impact of Registry Data on Health Care Policy
Brendon Stiles, MD
Feb 1, 2019 Link to How Far Would You Drive to Increase Your Chances of Cancer Survival?
Jan 29, 2019 Link to #GI19: Advancing Treatment for GI Cancers at ASCO GI 2019
Jan 29, 2019 Link to Exclusive: Highlights and Interviews from ASCO GI 2019
Mohamed Salem, MD
Jan 28, 2019 Link to ASCO GI 2019: A Multidisciplinary Approach to Providing Optimal Care for GI Cancer Patients
Yelena Janjigian, MD
Jan 28, 2019 Link to Combination Therapies: The Wave of the Future
Bassel Fouad El-Rayes, MD
Jan 25, 2019 Link to A Leader in the Field Discusses Advances in Pancreatic Cancer
Maria Doyle, MD
Jan 25, 2019 Link to The Explosion of Transplant Oncology
Harry Yoon, MD
Jan 25, 2019 Link to How Immunotherapy Is Transforming GI Cancer Treatment
Erik Mittra, MD
Jan 25, 2019 Link to Navigating the Evolving Landscape of Neuroendocrine Tumors
Dec 14, 2018 Link to Exclusive: Highlights and Interviews from ASH 2018
Chandler Park, MD, FACP
Dec 13, 2018 Link to ASH 2018: Research That Will Make a Difference for Tomorrow's Oncologist
Dec 13, 2018 Link to Breakthrough Trials, Global Health Initiatives and More at #ASH18
Myung Sun Kim, MD
Dec 13, 2018 Link to Thinking About Long-Term Treatment at ASH 2018
Sagar Patel, MD
Dec 13, 2018 Link to ASH 2018: Hope for SCD Within REACH
Aref Al-Kali, MD
Dec 13, 2018 Link to ASH 2018: The Current State of Myeloid Malignancies
Amber Yates, MD
Dec 13, 2018 Link to ASH 2018: How Social Media Has Helped My Career/Practice as a Hematologist
Jonathon B. Cohen, MD, MS
Dec 13, 2018 Link to ASH 2018: Novel Therapies for Relapsed/Refractory Aggressive Lymphomas